Abstract
Results The results of this study showed that SLIT group has a highly statistically significant reduction in the use of daily doses of the combination treatment (budesonide / formoterol) (p<0.0001), in comparison to control group (p=0.397). In addition, in the SLIT group there were 97% of the patients totally stopped both control and reliever medications in the final six months and only continued with SLIT. Moreover, there were more improvements in FVC and FEV1 in SLIT compared to control group. Additionally, these results revealed that SLIT significantly reduced the clinical outcome scores. There were no systematic (anaphylaxis) side effects reported with SLIT. Conclusions The results of this study suggest that SLIT has a significant role in controlling AA due to dust mite in children. Besides, the results suggest that SLIT is a safe medication for children with AA. Caution must be applied when using the results of this study in practice due to the retrospective design of this study, which means that the findings may not be transferable to routine clinical practice.
Highlights
A promising treatment for allergic asthma (AA) in children is the sublingual specific immunotherapy (SLIT) which targets mild or moderate persistent AA types
The Control group compared to fifty children (SLIT group) who were treated with the same combination therapy plus standardised extract 50/50 Dp / Df, a dust mite SLIT
The results of this study showed that SLIT group has a highly statistically significant reduction in the use of daily doses of the combination treatment (p
Summary
P80 - An evaluation of the efficacy and safety of a dust mite sublingual immunotherapy in allergic asthmatic children: a retrospective clinical data analysis over a three-year period. From 3rd Pediatric Allergy and Asthma Meeting (PAAM) Athens, Greece. From 3rd Pediatric Allergy and Asthma Meeting (PAAM) Athens, Greece. 17-19 October 2013
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
